Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
The question of whether an LHRH antagonist (such as degarelix) is really a better first-line hormone therapy than an LHRH agonist (e.g., leuprolide acetate) is still not fully answered.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, Degarelix, leuprolide, LHRH | Leave a Comment »
First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, LHRH, suppression, testosterone | 2 Comments »
A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, castration-resistance, LHRH, monotherapy, regimen | 1 Comment »
When all the drugs in the same class have the same general clinical impact, this is known as a “class effect.” As an example, all statins (hydroxymethylglutaryl–coenzyme A reductase inhibitors) will lower risk for certain types of cardiovascular event because they lower levels of cholesterol. That is a “class effect.”
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: agonist, antagonist, GnRH, LHRH | 2 Comments »
We are returning to “normal” today with the standard “news reports.” Today’s items deal with: Evolving biomarkers and new tests and their future application MRI in diagnosis, staging, and prognosis of prostate cancer Intraprostatic injection of LHRH agonists and antagonists: is it viable? Gefitinib in HRPC: no evident impact on quality of life
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: agonist, antagonist, biomarkers, gefitinib, Iressa, LHRH, magnetic resonance imaging, MRI | 2 Comments »
Klotz et al. have now published the complete results of one of the Phase III clinical trials designed to evaluate the effectiveness and the safety of degarelix — a second-generation LHRH antagonist — in the management of hormone-sensitive prostate cancer.
Filed under: Drugs in development, Management, Treatment | Tagged: antagonist, Degarelix, LHRH | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site